Nancy S. Scher

Approval summary for zoledronic acid for treatment of multiple myeloma and cancer bone metastases.

Amna Ibrahim, Nancy S. Scher, Grant Williams et al. · PubMed · 2003 · 198 citations

Medicine, Pharmacology, Pharmacotherapy +17

First FDA Approval of Dual Anti-HER2 Regimen: Pertuzumab in Combination with Trastuzumab and Docetaxel for HER2-Positive Metastatic Breast Cancer

Gideon M. Blumenthal, Nancy S. Scher, Patricia Cortazar et al. · Clinical Cancer Research · 2013 · 120 citations

Medicine, Oncology, Pharmacology +16

End points to establish the efficacy of new agents in the treatment of acute leukemia

Frederick R. Appelbaum, Daniel Rosenblum, R.J. Arceci et al. · Blood · 2006 · 91 citations · Full text

Medicine, Hematology, Oncology +9

FDA Approval Summary: Pertuzumab for Adjuvant Treatment of HER2-Positive Early Breast Cancer

Lynn Howie, Nancy S. Scher, Laleh Amiri‐Kordestani et al. · Clinical Cancer Research · 2018 · 68 citations

Medicine, Oncology, Pharmacology +17

U.S. Food and Drug Administration Drug Approval Summaries: Imatinib Mesylate, Mesna Tablets, and Zoledronic Acid

Martin H. Cohen, Ramzi Dagher, Donna Griebel et al. · The Oncologist · 2002 · 56 citations · Full text

Medicine, Oncology, Pharmacology +13